Abstract
The success of the phase III randomized controlled trials (RCTs) of disease-modifying therapies (DMTs) in relapsing–remitting multiple sclerosis (RRMS) [1–4] naturally led to exploration of their efficacy in both secondary progressive multiple sclerosis (SPMS) and primary progressive multiple sclerosis (PPMS). This chapter deals with trials of “conventional” disease-modifying therapies (DMTs), by which we mean drugs which are recognised as having therapeutic utility in the treatment of relapsing-remitting multiple sclerosis. These drugs are almost exclusively immunomodulatory, with particular emphasis on restricting the effector functions of T and B cells. Therefore as well as clinical benefit, these clinical trials help identify which pathways drive the poorly understood substrate of disease progression in humans. The bottom line is that almost all of these trials have been unsuccessful at meeting their primary endpoint in a clinically meaningful way. However, much has been learned about trial design and progress towards modest therapeutic activity has been made [5]. The contrast of therapeutic success of these DMTs in RRMS and their failure in progressive forms of disease is a valuable observation in itself. It suggests that transformative therapies in treatment of the progressive MS are unlikely to come from targeting the largely lymphocyte-driven inflammatory process which occurs early in the disease.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
IFN-(Multiple Sclerosis Study Group). Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter-randomised, double blind, placebo-controlled trial. Neurology. 1993;43:655–61.
Jacobs LD, Cookfair DL, Rudick RA, et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. Ann Neurol. 1996;39:285–94.
PRISMS (Prevention of relapses and disability by interferon beta-1a subcutaneously in multiple sclerosis) Study Group. Randomized double-blind placebo controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. Lancet. 1998;352:1498–504.
Johnson KP, Brooks BR, Cohen JA. Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability. Copolymer 1 Multiple Sclerosis Study Group. Neurology. 1998;50:701–8.
Ontaneda D, Fox RJ, Chataway J. Clinical trials in progressive multiple sclerosis: lessons learned and future perspectives. Lancet Neurol. 2015;14(2):208–23.
Mahad DH, Trapp BD, Lassmann H. Pathological mechanisms in progressive multiple sclerosis. Lancet Neurol. 2015;14(2):183–93.
Schumacher FA, Beeve GW, Kibler RF, et al. Problems of experimental trials of therapy in multiple sclerosis. Ann N Y Acad Sci. 1965;122:552–68.
Poser CM, Paty DW, Scheinberg LC, et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol. 1983;1:227–31.
McDonald WI, Compston A, Edan G, et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol. 2001;50:121–7.
Polman CH, Reingold SC, Edan G, et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald criteria”. Ann Neurol. 2005;58:840–6.
Polman CH, Reingold SC, Banwell B. Diagnostic criteria for multiple sclerosis: 2010 revisions to the “McDonald criteria”. Ann Neurol. 2011;69:292–302.
Thompson AJ, Polman CH, Miller DH, et al. Primary progressive multiple sclerosis. Brain. 1997;120:1085–96.
Lublin FD, Reingold SC. Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Neurology. 1996;46:907–11.
Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology. 1983;33:1444–52.
Cutter GR, Baier ML, Rudick RA, et al. Development of a multiple sclerosis functional composite as a clinical trial outcome measure. Brain. 1999;122:871–82.
Wilkins A, Scolding N. Protecting axons in multiple sclerosis. Mult Scler. 2008;14:1013–25.
Stys PK, et al. Will the real multiple sclerosis please stand up? Nat Rev Neurosci. 2012;13(7):507–14.
Boggild M, et al. Multiple sclerosis risk sharing scheme: two year results of clinical cohort study with historical comparator. BMJ. 2009;339:b4677.
Palace J, et al. UK multiple sclerosis risk-sharing scheme: a new natural history dataset and an improved Markov model. BMJ Open. 2014;4(1):e004073.
Hartung HP, Aktas O. Evolution of multiple sclerosis treatment: next generation therapies meet next generation efficacy criteria. Lancet Neurol. 2011;10(4):293–5.
Lublin FD, Reingold SC. Placebo-controlled clinical trials in multiple sclerosis: ethical considerations. National Multiple Sclerosis Society (USA) Task Force on Placebo-Controlled Clinical Trials in MS. Ann Neurol. 2001;49:677–81.
McFarland HF, Reingold SC. The future of multiple sclerosis therapies: redesigning multiple sclerosis clinical trials in a new therapeutic era. Mult Scler. 2005;11:669–76.
Polman CH, Reingold SC, Barkhof F, et al. Ethics of placebo-controlled clinical trials in multiple sclerosis: a reassessment. Neurology. 2008;70:1134–40.
European Study Group on Interferon beta-1b in Secondary Progressive MS. Placebo-controlled multicentre randomized trial of interferon beta-1b in treatment of secondary progressive multiple sclerosis. Lancet. 1998;352:1491–7.
Miller DH, Molyneux PD, Barker GJ, et al. Effect of interferon-1b on magnetic resonance imaging outcomes in secondary progressive multiple sclerosis: results of a European multicenter, randomized, double-blind, placebo controlled trial. Ann Neurol. 1999;46:850–9.
Brex PA, Molyneux PD, Smiddy P, et al. The effect of IFNbeta-1b on the evolution of enhancing lesions in secondary progressive MS. Neurology. 2001;57:2185–90.
Molyneux PD, Kappos L, Polman C. The effect of interferon beta-1b treatment on MRI meaures of cerebral atrophy in secondary progressive multiple sclerosis. European Study Group on Interferon beta-1b in secondary progressive multiple sclerosis. Brain. 2000;123:2256–63.
Molyneux PD, Barker GJ, Barkhof F, et al. Clinical-MRI correlations in a European trial of interferon beta-1b in secondary progressive MS. Neurology. 2001;57:2191–7.
Kappos L, Weinshenker B, Pozzilli C, et al. Interferon beta-1b in secondary progressive MS: a combined analysis of the two trials. Neurology. 2004;63:1779–87.
Panitch H, Miller A, Paty D, Weinshenker B, et al. Interferon beta-1b in secondary progressive MS: results from a 3-year controlled study. Neurology. 2004;63:1788–95.
Secondary Progressive Efficacy Clinical Trial of Recombinant Interferon-Beta-1a in MS (SPECTRIMS) Study Group. Randomized controlled trial of interferon-beta-1a in secondary progressive MS: clinical results. Neurology. 2001;56:1496–504.
Patten SB, Metz LM. SPECTRIMS Study Group. Interferon beta-1a and depression in secondary progressive MS: data from the SPECTRIMS Trial. Neurology. 2002;59:744–6.
Li DK, Zhao GJ, Paty DW, University of British Columbia MS/MRI Analysis Research Group. The SPECTRIMS Study Group. Randomized controlled trial of interferon-beta-1a in secondary progressive MS: MRI results. Neurology. 2001;56:1505–13.
Cohen JA, Cutter GR, Fischer JS, et al. Benefit of interferon beta-1a on MSFC progression in secondary progressive MS. Neurology. 2002;59:679–87.
Rudick R, Polman C, Cohen J, et al. Assessing disability progression with the Multiple Sclerosis Functional Composite. Mult Scler. 2009;15:984–97.
Andersen O, Elovaara I, Farkkila M, et al. Multicentre, randomised, double blind, placebo controlled, phase III study of weekly, low dose, subcutaneous interferon beta-1a in secondary progressive multiple sclerosis. J Neurol Neurosurg Psychiatry. 2004;75:706–10.
Comi G, Fillippi M, Barkhof F, et al. Effect of early interferon treatment on conversion to clinically definite multiple sclerosis: a randomized study. Lancet. 2001;357:1576–82.
Jacobs L, Beck RW, Simon JH, et al. Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. N Engl J Med. 2000;343:898–904.
Hartung HP, Gonsette R, Konig N, et al. Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial. Lancet. 2002;360:2018–25.
Krapf H, Morrissey SP, Zenker O, Zwingers T, Gonsette R, Hartung HP, MIMS Study Group. Effect of mitoxantrone on MRI in progressive MS: results of the MIMS trial. Neurology. 2005;65:690–5.
Edan G, Miller D, Clanet M, et al. Therapeutic effect of mitoxantrone combined with methylprednisolone in multiple sclerosis: a randomised multicentre study of active disease using MRI and clinical criteria. J Neurol Neurosurg Psychiatry. 1997;62:112–8.
Esposito F, Radaelli M, Martinelli V, et al. Comparative study of mitoxantrone efficacy profile in patients with relapsing-remitting and secondary progressive multiple sclerosis. Mult Scler. 2010;16:1490–9.
Marriott JJ, Miyasaki JM, Gronseth G, O’Connor PW, Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Evidence Report: the efficacy and safety of mitoxantrone (Novantrone) in the treatment of multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology. 2010;74:1463–70.
Ghalie RG, Mauch E, Edan G, Hartung HP, et al. A study of therapy related acute leukaemia after mitoxantrone therapy for multiple sclerosis. Mult Scler. 2002;8:441–5.
Ellis R, Boggild M. Therapy-related acute leukaemia with mitoxantrone: what is the risk and can we minimise it? Mult Scler. 2009;15:505–8.
Martinelli Boneschi F, Rovaris M, Capra R, Comi G. Mitoxantrone for multiple sclerosis. Cochrane Database Syst Rev. 2005;4:CD002127. Review 83.
Hommes OR, Sorensen PS, Fazekas F, et al. Intravenous immunoglobulin in secondary progressive multiple sclerosis: randomised placebo-controlled trial. Lancet. 2004;364:1149–56.
Fazekas F, Sorensen PS, Filippi M, et al. MRI results from the European study on intravenous immunoglobulin in secondary progressive multiple sclerosis (ESIMS). Mult Scler. 2005;11:433–40.
Filippi M, Rocca MA, Pagani E, et al. European study on intravenous immunoglobulin in multiple sclerosis: results of magnetization transfer magnetic resonance imaging analysis. Arch Neurol. 2004;61:1409–12.
Gray O, McDonnell GV, Forbes RB. Intravenous immunoglobulins for multiple sclerosis. Cochrane Database Syst Rev. 2003;3:CD002936. doi:10.1002/14651858.CD002936.
Goodkin DE, Kinkel RP, Weinstock-Guttman B. A phase II study of i.v. methylprednisolone in secondary-progressive multiple sclerosis. Neurology. 1998;51:239–45.
Ciccone A, Beretta S, Brusaferri F, Galea I, Protti A, Spreafico C. Corticosteroids for the longterm treatment in multiple sclerosis. Cochrane Database Syst Rev. 2008;1:CD006264. doi:10.1002/14651858.CD006264.pub2.
Cook SD, Devereux C, Troiano R, et al. Effect of total lymphoid irradiation in chronic progressive multiple sclerosis. Lancet. 1986;1:1405–9.
Gordon PA, Carroll DJ, Etches WS, et al. A double-blind controlled pilot study of plasma exchange versus sham apheresis in chronic progressive multiple sclerosis. Can J Neurol Sci. 1985;12:39–44.
Perini P, Calabrese M, Tiberio M, Ranzato F, Battistin L, Gallo P. Mitoxantrone versus cyclophosphamide in secondary-progressive multiple sclerosis: a comparative study. J Neurol. 2006;253:1034–40.
Perini P, Gallo P. Cyclophosphamide is effective in stabilizing rapidly deteriorating secondary progressive multiple sclerosis. J Neurol. 2003;250:834–8.
Schwartzman RJ, Simpkins N, Alexander GM, et al. High-dose cyclophosphamide in the treatment of multiple sclerosis. CNS Neurosci Ther. 2009;15:118–27.
Lugaresi A, Caporale C, Farina D, et al. Low-dose oral methotrexate treatment in chronic progressive multiple sclerosis. Neurol Sci. 2001;22:209–10.
Rice GP, Filippi M, Comi G. Cladribine and progressive MS: clinical and MRI outcomes of a multicenter controlled trial Cladribine MRI Study Group. Neurology. 2000;54:1145–55.
Wiendl H, Kieseier BC, Weissert R. Treatment of active secondary progressive multiple sclerosis with treosulfan. J Neurol. 2007;254:884–9.
Mancardi GL, Murialdo A, Rossi P, et al. Autologous stem cell transplantation as rescue therapy in malignant forms of multiple sclerosis. Mult Scler. 2005;11:367–71.
Reston JT, Uhl S, Treadwell JR, Nash RA, Schoelles K. Autologous hematopoietic cell transplantation for multiple sclerosis: a systematic review. Mult Scler. 2011;17:204–13.
Jeffery DR. The argument against the use of cyclophosphamide and mitoxantrone in the treatment of multiple sclerosis. J Neurol Sci. 2004;223:41–6.
Polman CH, et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med. 2006;354(9):899–910.
Bloomgren G, et al. Risk of natalizumab-associated progressive multifocal leukoencephalopathy. N Engl J Med. 2012;366(20):1870–80.
Steiner D, et al. Natalizumab versus placebo in patients with secondary progressive multiple sclerosis (SPMS): results from ASCEND, a Multicenter, Double-blind, Placebo-Controlled, Randomized Phase 3 Clinical Trial. Am Acad Neurol. 2016:P009.
Kappos L, et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med. 2010;362(5):387–401.
Calabresi PA, et al. Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Neurol. 2014;13(6):545–56.
Kappos L, et al. Safety and efficacy of siponimod (BAF312) in patients with relapsing-remitting multiple sclerosis: dose-blinded, randomized extension of the phase 2 BOLD study. JAMA Neurol. 2016;73(9):1089–98.
Selmaj K, et al. Siponimod for patients with relapsing-remitting multiple sclerosis (BOLD): an adaptive, dose-ranging, randomised, phase 2 study. Lancet Neurol. 2013;12(8):756–67.
Kappos L, Bar-Or A, Cree B, et al. Efficacy and safety of siponimod in secondary progressive multiple sclerosis—Results of the placebo controlled, double-blind, Phase III EXPAND study. ECTRIMS 2016. London, UK: ECTRIMS Online Library; 2016.
Kappos L, Bar-Or A, Cree B, Fox R, Giovannoni G, Gold R, Vermersch P, Arnould S, Sidorenko T, Wolf C, Wallström E, Dahlke F. 002—Efficacy of siponimod in secondary progressive multiple sclerosis: results of the phase 3 study. Boston, MA, USA: 69th Annual Meeting of the American Academy of Neurology; 2017.
Paolillo A, Coles AJ, Molyneux PD, et al. Quantitative MRI in patients with secondary progressive MS treated with monoclonal antibody Campath1H. Neurology. 1999;53:751–7.
Confavreux C, Vukusic S, Moreau T, Adeleine P. Relapses and progression of disability in multiple sclerosis. N Engl J Med. 2000;343:1430–8.
Confavreux C, Vukusic S, Adeleine P. Early clinical predictors and progression of irreversible disability in multiple sclerosis: an amnesic process. Brain. 2003;126:770–82.
Kremenchutzky M, Rice GP, Baskerville J, Wingerchuk DM, Ebers GC. The natural history of multiple sclerosis: a geographically based study 9: observations on the progressive phase of the disease. Brain. 2006;129:584–94.
Koch M, Kingwell E, Rieckmann P, Neurologists THUBCMSC. The natural history of secondary progressive multiple sclerosis. J Neurol Neurosurg Psychiatry. 2010;81:1039–43.
Koch M, Kingwell E, Rieckmann P, Tremlett H. The natural history of primary progressive multiple sclerosis. Neurology. 2009;73:1996–2002.
Tremlett H, Zhao Y, Devonshire V, UBC Neurologists. Natural history comparisons of primary and secondary progressive multiple sclerosis reveals differences and similarities. J Neurol. 2009;256:374–81.
Cottrell DA, Kremenchutzky M, Rice GP, Hader W, Baskerville J, Ebers GC. The natural history of multiple sclerosis: a geographically based study. 6. Applications to planning and interpretation of clinical therapeutic trials in primary progressive multiple sclerosis. Brain. 1999;122:641–7.
Montalban X, Thompson AJ. Workshop on primary progressive multiple sclerosis: meeting summary. Mult Scler. 2002;8:177–8.
Wolinsky JS. PROMiSe Study Group. The diagnosis of primary progressive multiple sclerosis. J Neurol Sci. 2003;206:145–52.
Leary SM, Miller DH, Stevenson VL, et al. Interferon beta-1a in primary progressive MS: an exploratory, randomized, controlled trial. Neurology. 2003;60:44–51.
Montalban X, Sastre-Garriga J, Tintore M, et al. A single-center, randomized, double-blind, placebo-controlled study of interferon beta-1b on primary progressive and transitional multiple sclerosis. Mult Scler. 2009;15:1195–205.
Rojas JI, Romano M, Ciapponi A, Patrucco L, Cristiano E. Interferon beta for primary progressive multiple sclerosis. Cochrane Database Syst Rev. 2009;1:CD006643. Review. Update in: Cochrane Database Syst Rev. 2010;(1):CD006643.
Bornstein MB, Miller A, Slagle S, et al. A placebo-controlled, double-blind, randomized, twocenter, pilot trial of Cop 1 in chronic progressive multiple sclerosis. Neurology. 1991;41:533–9.
Wolinsky JS, Narayana PA, O’Connor P, et al. Glatiramer acetate in primary progressive multiple sclerosis: results of a multinational, multicenter, double-blind, placebo-controlled trial. Ann Neurol. 2007;61:14–24.
Sajja BR, Narayana PA, Wolinsky JS, Ahn CW, PROMiSe Trial MRSI. Group. Longitudinal magnetic resonance spectroscopic imaging of primary progressive multiple sclerosis patients treated with glatiramer acetate: multicenter study. Mult Scler. 2008;14:73–80.
Wolinsky JS, Shochat T, Weiss S, Ladkani D. PROMiSe Trial Study Group. Glatiramer acetate treatment in PPMS: why males appear to respond favorably. J Neurol Sci. 2009;286:92–8.
Bornstein MB, Miller A, Slagle S, et al. A pilot trial of Cop 1 in exacerbating-remitting multiple sclerosis. N Engl J Med. 1987;317:408–14.
Lublin F, et al. Oral fingolimod in primary progressive multiple sclerosis (INFORMS): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet. 2016;387(10023):1075–84.
Hawker K, O’Connor P, Freedman MS, OLYMPUS Trial Group. Rituximab in patients with primary progressive multiple sclerosis: results of a randomized double-blind placebo-controlled multicenter trial. Ann Neurol. 2009;66:460–71.
Hauser SL, Waubant E, Arnold DL, HERMES Trial Group. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med. 2008;358:676–88.
Kappos L, et al. Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial. Lancet. 2011;378(9805):1779–87.
Hauser SL, et al. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med. 2008;358(7):676–88.
Montalban X, et al. Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis. N Engl J Med. 2017;376(3):209–20.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2018 Springer International Publishing AG
About this chapter
Cite this chapter
Hutchinson, M., Hunt, D.P.J. (2018). Trials of Licenced RRMS DMTs in Progressive MS. In: Wilkins, A. (eds) Progressive Multiple Sclerosis. Springer, Cham. https://doi.org/10.1007/978-3-319-65921-3_8
Download citation
DOI: https://doi.org/10.1007/978-3-319-65921-3_8
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-65920-6
Online ISBN: 978-3-319-65921-3
eBook Packages: MedicineMedicine (R0)